Mydecine

Mydecine
IndustryPharmaceutical; Psychedelic medicine
Founded2020; 6 years ago (2020) in Denver, Colorado
Headquarters
Vancouver, British Columbia
,
Canada
Websitemydecine.com

Mydecine Innovations Group, or simply Mydecine, is an American and Canadian pharmaceutical company that is developing psychedelics and entactogens as medicines.

In August 2022, it was reported that Mydecine was experiencing financial difficulties and might cease operations. However, the company was able to obtain more funding and did not shutdown. Mydecine made the first legal import of magic mushrooms into Canada in 2021.

Mydecine's drug candidates include the psychedelics psilocybin (MYCO-001, MYCO-003), MYCO-004 (a patch-delivered tryptamine), and MYCO-005 (a novel aza psilocin analogue with putatively better safety) and the novel MDMA-like entactogens MYCO-002 (putatively safer), MYCO-006 (short-acting), and MYCO-007 (short-acting).

Although the chemical structures of most of its drug candidates have not been disclosed, Mydecine has patented 5-BZT-MDMA (MY100) and 6-BZT-MDMA (MY101) as short-acting MDMA analogues.

See also

References

  1. 1 2 Simonelli, Gary (10 April 2023). "The Use of AI Technology is Increasing the Potential of Mydecine Innovations Group to Successfully Commercialize Psychedelic Drug Candidates". CEOCFO. Retrieved 29 January 2025.
  2. 1 2 Koning E, Solmi M, Brietzke E (August 2024). "The Influence of Stakeholder Interests on Safety Outcome Reporting in Psychedelic Research and Implications for Science Communication". Trends Psychiatry Psychother. doi:10.47626/2237-6089-2024-0866. PMC 12904264. PMID 39088699. The company Mydecine Innovations Group developed a proprietary compound MYCO-005, which mimics the active ingredient in psilocybin, but with a more rapid onset and shorter duration of action.84 [...]
  3. 1 2 Dunne, Rowan (24 April 2023). "Mydecine's MDMA with rapid onset and a short duration shows promising results". Mugglehead Investment Magazine. Retrieved 29 January 2025.
  4. 1 2 3 "Mydecine Looks Set to Shutter; MindMed Gains 'Meme Stock' Status; atai 'Streamlilnes' Pipeline; California Decrim. Bill Gutted". Psychedelic Alpha. 19 August 2022. Retrieved 29 January 2025.
  5. 1 2 Borchardt, Debra (17 August 2022). "Psilocybin Company Mydecine Is Down To $300k In Cash". Green Market Report. Retrieved 29 January 2025. Just last month Mydecine announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs had been specifically designed by experts at Mydecine to have a shorter half-life than traditional MDMA. The company has named this family of novel molecules MYCO-006 and applied for patent coverage with the World Intellectual Property Organization.
  6. ↑ Gnam, Jared (11 December 2020). "Mydecine to make first legal import of psilocybin mushrooms into Canada". Mugglehead Investment Magazine. Retrieved 29 January 2025.
  7. ↑ Lansdowne, Laura Elizabeth (19 February 2021). "Behind the World-First Export of Jamaican Psilocybin Mushrooms". Neuroscience from Technology Networks. Retrieved 29 January 2025.
  8. ↑ "Psilocybin - Mydecine Innovations Group - AdisInsight". adisinsight.springer.com.
  9. ↑ "Delving into the Latest Updates on MYCO-001 with Synapse". Synapse. 23 January 2025. Retrieved 29 January 2025.
  10. ↑ "Delving into the Latest Updates on MYCO-003 with Synapse". Synapse. 23 January 2025. Retrieved 29 January 2025.
  11. ↑ "MYCO 004 - AdisInsight". adisinsight.springer.com.
  12. ↑ "Delving into the Latest Updates on MYCO-004 with Synapse". synapse.patsnap.com.
  13. ↑ "Research programme: second generation psilocin analogs - Mydecine Innovations Group - AdisInsight". adisinsight.springer.com.
  14. ↑ "Delving into the Latest Updates on MYCO-005 with Synapse". Synapse. 1 November 2024. Retrieved 1 November 2024.
  15. ↑ "MYCO 002 - AdisInsight". adisinsight.springer.com.
  16. ↑ "Delving into the Latest Updates on MYCO-002 with Synapse". synapse.patsnap.com.
  17. ↑ "Research programme: short acting methylenedioxymethamphetamine analogs - Mydecine Innovations Group - AdisInsight". adisinsight.springer.com.
  18. ↑ "Delving into the Latest Updates on MYCO-006 with Synapse". synapse.patsnap.com.
  19. ↑ "Delving into the Latest Updates on MYCO-007 with Synapse". synapse.patsnap.com.
  20. ↑ "2309151616480990.pdf" (PDF). Retrieved 23 October 2024. MYCO - 006 and 007 represent families of molecules that are based on MDMA molecules. MYCO -006 and MYCO – 007 have been developed in order to reduce the overall acute experience time of Generation 1 MDMA by increasing the metabolism properties of the drug.
  21. ↑ Mydecine Innovations Group (19 July 2022). "Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs". GlobeNewswire News Room. Retrieved 23 October 2024. Mydecine [...] announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs have been specifically designed by experts at Mydecine to have a shorter half life than traditional MDMA. The Company has named this family of novel molecules MYCO-006 and have applied for patent coverage with the World Intellectual Property Organization.
  22. ↑ Mydecine (5 January 2024). "Novel short-acting psychoactive compounds of the mdma class". Google Patents. Retrieved 23 October 2024.
  23. ↑ "1-(1,3-benzoxathiol-5-yl)-N-methylpropan-2-amine". PubChem. Retrieved 23 October 2024.
  24. ↑ "1-(1,3-benzoxathiol-5-yl)-N,N-dimethylpropan-2-amine". PubChem. Retrieved 23 October 2024.